Početna › Imunološki sustav i poremećaji › Oregon
Kliničke studije za Imunološki sustav i poremećaji u državi Oregon
9 studija za Imunološki sustav i poremećaji traži sudionike na lokacijama u državi Oregon.
Gradovi u državi Oregon
Službeni tekst studije (engleski)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07192471A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- i još 9
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 17. ruj 2026. · NCT04242095A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT06948318A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Providence Portland Medical Center, Portland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07075185A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 3, Portland
U tijeku regrutacijaFaza 2
Od 18 do 74 godina · Oba spola · Ažurirano 12. kol 2026. · NCT07037901Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 7. srp 2026. · NCT07216443CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Providence Neurological Specialties West, Portland
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 16. tra 2026. · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Oregon Health and Science University, Portland
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 15. pro 2025. · NCT06619561Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.